Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
Recruiting
100 enrolled
NeoLATC
Recruiting
120 enrolled
ALCG-01
Recruiting
400 enrolled
Oncomabs
Terminated
80 enrolled
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
Recruiting
30 enrolled
International Multicentric Study ARON-1
Recruiting
1,220 enrolled
Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
Completed
327 enrolled
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Completed
662 enrolled
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
Recruiting
270 enrolled
Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab
Completed
31 enrolled
DELINOR
Completed
5,279 enrolled 10 charts
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
Active not recruiting
100 enrolled
The Immune Assessment of PD-1 Antibody Therapy in Tumor
Recruiting
3,000 enrolled
APiTOXMM
Recruiting
160 enrolled
Imaging FDG Flare in Melanoma
Completed
21 enrolled 10 charts
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
Completed
851 enrolled
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]
Completed
304 enrolled
EROS
Recruiting
80 enrolled
A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC
Recruiting
70 enrolled
Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab
Completed
150 enrolled
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Completed
600 enrolled
Axitinib Therapy Management Study
Withdrawn
TREATMENT
Unknown
200 enrolled
NSCLC
Unknown
60 enrolled
I-STOP
Unknown
300 enrolled
Emulation of the KEYNOTE-189 Trial Using Electronic Health Records
Completed
1,854 enrolled
PORTRAIT
Recruiting
100 enrolled
Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden
Completed
1,975 enrolled
PASIP
Completed
25 enrolled
ST-ICI
Completed
150 enrolled
Microbiome Immunotherapy Toxicity and Response Evaluation
Unknown
1,800 enrolled
QUASAR
Unknown
42 enrolled
PROBES
Unknown
47 enrolled
Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients
Completed
40 enrolled
Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China
Unknown
30 enrolled
Esporta
Completed
40 enrolled
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
Unknown
300 enrolled
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Unknown
400 enrolled
A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients
Unknown
60 enrolled
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
Unknown
100 enrolled
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
Unknown
80 enrolled
NIRPA
Completed
27 enrolled
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Unknown
4,724 enrolled
A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy
Unknown
1,000 enrolled